3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
66
Carcinoma, Renal Cell
38
Liver Neoplasms
20
Neoplasm Metastasis
17
Carcinoma, Non-Small-Cell Lung
16
Neoplasms
15
Breast Neoplasms
15
Melanoma
13
Thyroid Neoplasms
10
Leukemia, Myeloid, Acute
10
Sarcoma
9
Lung Neoplasms
8
Kidney Neoplasms
8
Prostatic Neoplasms
7
Ovarian Neoplasms
7
Urinary Bladder Neoplasms
6
Pancreatic Neoplasms
6
Glioblastoma
6
Brain Neoplasms
6
Colorectal Neoplasms
5
Carcinoma, Medullary
5
Thyroid Carcinoma, Anaplastic
4
Stomach Neoplasms
4
Rectal Neoplasms
4
Gliosarcoma
4
Gallbladder Neoplasms
4
Colonic Neoplasms
4
Breast Neoplasms, Male
4
Thyroid Diseases
3
Thyroid Cancer, Papillary
3
Interventions
Cisplatin
8
Etoposide
6
Paclitaxel
5
Ifosfamide
4
Sunitinib
3
Oxaliplatin
3
Cyclophosphamide
3
Brentuximab Vedotin
3
tremelimumab
2
pembrolizumab
2
etoposide phosphate
2
durvalumab
2
Sirolimus
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Dexamethasone
2
Carboplatin
2
Bleomycin
2
Bevacizumab
2
tozuleristide
1
rolapitant
1
ribociclib
1
pegfilgrastim
1
pazopanib
1
olaparib
1
fosaprepitant
1
fludarabine phosphate
1
fludarabine
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Germ Cell and Embryonal
×
Sorafenib
×
Clear all
NCT00772694
2008-10-24
GCT
Fondation Wygrajmy Zdrowie
Phase 2
Unknown
20 enrolled